Literature DB >> 12909460

Hepatitis C virus infection: when silence is deception.

Vito Racanelli1, Barbara Rehermann.   

Abstract

Hepatitis C virus (HCV) uses complex and unique mechanisms to prevent, evade or subvert innate and adaptive immune responses and to establish persistent infection and chronic hepatitis. Recently developed experimental systems have significantly facilitated the analysis of HCV replication, virus-host interaction and pathogenesis of chronic hepatitis and have provided new insights into the mechanisms of HCV clearance and persistence.

Entities:  

Mesh：

Year:  2003        PMID： 12909460     DOI： 10.1016/s1471-4906(03)00178-9

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  27 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 4.  B cells in transplant tolerance and rejection: friends or foes?

Authors:  Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun
Journal:  Transpl Int       Date:  2020-01       Impact factor: 3.782

Review 5.  Hepatitis C.

Authors:  Daniel P Webster; Paul Klenerman; Geoffrey M Dusheiko
Journal:  Lancet       Date:  2015-02-14       Impact factor: 79.321

Review 6.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

7.  Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules.

Authors:  Vito Racanelli; Maria Antonia Frassanito; Patrizia Leone; Maria Galiano; Valli De Re; Franco Silvestris; Franco Dammacco
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 8.  The Immune Fulcrum: Regulatory T Cells Tip the Balance Between Pro- and Anti-inflammatory Outcomes upon Infection.

Authors:  Laura E Richert-Spuhler; Jennifer M Lund
Journal:  Prog Mol Biol Transl Sci       Date:  2015-08-18       Impact factor: 3.622

9.  Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line.

Authors:  Yizhong Wang; Jieliang Li; Xu Wang; Li Ye; Yu Zhou; Rebecca M Thomas; Wenzhe Ho
Journal:  Innate Immun       Date:  2013-03-25       Impact factor: 2.680

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.